Selected baseline characteristics according to time from symptom onset to needle
| Time from symptom onset to needle | P value | ||||
| 0–3 hours (n=316) | >3 hours (n=92) | ||||
| N* | N* | ||||
| Age at inclusion (years), median (IQR) | 316 | 72 (64–81) | 92 | 74 (67–81) | 0.27 |
| Female sex, no. (%) | 316 | 159 (50.3%) | 92 | 50 (54.3%) | 0.55 |
| NIHSS, median (IQR) | 316 | 17 (13–20) | 92 | 17 (12–20) | 0.8 |
| Pre-stroke mRS, no. (%) | 316 | 92 | 0.8 | ||
| 0 | 269 (85.1%) | 77 (83.7%) | |||
| 1 | 46 (14.6%) | 15 (16.3%) | |||
| 4 | 1 (0.3%) | 0 (0.0%) | |||
| Weight (kg), median (IQR) | 293 | 75 (65–85) | 89 | 75 (68–85) | 0.81 |
| Systolic blood pressure (mmHg), median (IQR) | 312 | 147 (130–160) | 91 | 149 (135–163) | 0.58 |
| Diastolic blood pressure (mmHg), median (IQR) | 310 | 80 (70–90) | 90 | 80 (71–90) | 0.99 |
| Heart rate (beats/min), median (IQR) | 309 | 75 (64–88) | 88 | 74 (63–86) | 0.86 |
| Previous ischemic stroke, no. (%) | 304 | 30 (9.5%) | 90 | 11 (12.0%) | 0.55 |
| Previous transient ischemic attack, no. (%) | 300 | 14 (4.4%) | 89 | 7 (7.6%) | 0.28 |
| History of hypertension, no. (%) | 306 | 185 (58.5%) | 92 | 54 (58.7%) | 1 |
| History of atrial fibrillation, no. (%) | 299 | 28 (8.9%) | 88 | 11 (12.0%) | 0.42 |
| History of hypercholesterolemia, no. (%) | 298 | 98 (31.0%) | 89 | 33 (35.9%) | 0.38 |
| Previous intracerebral hemorrhage, no. (%) | 307 | 2 (0.6%) | 90 | 0 (0.0%) | 1 |
| Prior myocardial infarction, no. (%) | 301 | 37 (11.7%) | 89 | 4 (4.3%) | 0.047 |
| Warfarin or other anticoagulant, no. (%) | 316 | 11 (3.5%) | 92 | 5 (5.4%) | 0.37 |
| Aspirin, no. (%) | 316 | 84 (26.6%) | 92 | 21 (22.8%) | 0.5 |
| Statin or other lipid lowering agent, no. (%) | 316 | 91 (28.8%) | 92 | 28 (30.4%) | 0.79 |
| Blood glucose level (mmol/L), median (IQR) | 303 | 6.5 (5.7–7.5) | 82 | 6.6 (5.9–7.6) | 0.46 |
| INR, median (IQR) | 253 | 1.0 (1.0–1.1) | 67 | 1.0 (1.0–1.1) | 0.62 |
| Platelet count (×109/L), median (IQR) | 314 | 225 (187–268) | 91 | 228 (192–280) | 0.28 |
| Hemoglobin (g/L), median (IQR) | 316 | 137 (125–146) | 92 | 137 (123–147) | 0.84 |
| Glomerular filtration rate (mL/min), median (IQR) | 316 | 76 (62–90) | 92 | 74 (60–90) | 0.89 |
| Baseline imaging, no. (%) | 316 | 92 | <0.001 | ||
| CT | 177 (56.0%) | 28 (30.4%) | |||
| MRI | 137 (43.4%) | 63 (68.5%) | |||
| Both | 2 (0.6%) | 1 (1.1%) | |||
| ASPECTS (core lab), median (IQR) | 315 | 8.0 (7.0–9.0) | 92 | 8.0 (6.0–8.5) | 0.004 |
| Baseline intracranial occlusion site, no. (%) | 316 | 92 | 0.99 | ||
| Distal ICA - I | 12 (3.8%) | 4 (4.3%) | |||
| Distal ICA - I and M1 | 2 (0.6%) | 0 (0.0%) | |||
| Distal ICA - L | 41 (13.0%) | 13 (14.1%) | |||
| Distal ICA - T | 37 (11.7%) | 8 (8.7%) | |||
| Distal M1 | 96 (30.4%) | 29 (31.5%) | |||
| Distal M2 | 3 (0.9%) | 1 (1.1%) | |||
| Proximal M1 | 110 (34.8%) | 34 (37.0%) | |||
| Proximal M2 | 15 (4.7%) | 3 (3.3%) | |||
| Tandem lesion, no. (%) | 316 | 45 (14.2%) | 92 | 18 (19.6%) | 0.25 |
ASPECTS, Alberta Stroke Programme Early CT Score; ICA, internal carotid artery; INR, International normalized ratio; mRS, modified Rankin Scale; N*, number of patients with non-missing data; NIHSS, National Institutes of Health Stroke Scale.